COMMUNIQUÉS West-GlobeNewswire

Cronos Group Inc. to Hold 2025 Third Quarter Earnings Conference Call on November 6, 2025
23/10/2025
TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 third quarter earnings conference call on Thursday, November 6, 2025 at 8:30 a.m. ET [...]
Tango Therapeutics Announces $225 Million Financing
23/10/2025
Financing participants include Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, Nextech, Invus, Adage Capital Management LP, Boxer Capital Management, Logos Capital, Nantahala Capital [...]
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
23/10/2025
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development [...]
BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
LONG BEACH, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report third quarter 2025 financial results after market close [...]
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
23/10/2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s ( [...]
Solana Company (NASDAQ: HSDT) Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services
23/10/2025
NEWTOWN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT or the “ Company ”) announced that it has entered into agreements with Helius and Twinstake (each, a “ Provider ,” and collectively, the “ [...]
Synfini Selected for SLAS 2026 Innovation AveNEW Showcase
23/10/2025
Company Selected to Demonstrate its Novel AI Foundry That Unites Virtual and Physical Chemistry, Reducing the Time and Cost of Modern Molecular Discovery MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Synfini , [...]
Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide
23/10/2025
The health tech company adds more than 1,700 Albertsons Cos. pharmacies to its partnership base of over 37,000 locations ESTERO, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Visory Health , a patient-first health tech [...]
Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
23/10/2025
Collaboration with Monash University to Address a Large Pharmaceutical Opportunity MELBOURNE, Australia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company [...]
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
23/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American [...]
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 Company to host conference call and webcast on Thursday, November 6 th at 8:30am EST AUSTIN, Texas, October 23, 2025 -- EDAP TMS SA (Nasdaq: EDAP [...]
TRIDENT, a dedicated stroke outcomes trial in patients with a history of intracerebral hemorrhage (ICH), demonstrates the potential advantages of intensive blood pressure treatment with low-dose triple combination therapyTRIDENT, a dedicate
23/10/2025
GMRx2 significantly reduced the risk of recurrent stroke when added to standard of care compared to placebo Trial results were presented during a plenary session of the World Stroke Congress 2025 in Barcelona London, UK [...]
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
23/10/2025
Appointments for SVP of Clinical Operations, VP of Translational Science, and Head of Project and Portfolio Management will strengthen Amphista’s clinical development capabilities and accelerate its ambition to bring [...]
Conavi Medical to Highlight Novasight Hybrid™ Imaging at TCT 2025
23/10/2025
Company to Participate in Educational Imaging Sessions and Feature Hybrid IVUS/OCT Imaging Technology TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a commercial-stage [...]
Redhook Brewing Launches Redhook 81, Celebrating Pacific Northwest Roots and the Spirit of Hard Work
23/10/2025
Redhook 81, a Cold One for Quittin’ Time SEATTLE, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Redhook Brewing , creator of the hardest working beer in the fridge and a craft brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: [...]
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
23/10/2025
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 23, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), INmune Bio Inc. (NASDAQ: INMB), a clinical- [...]
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. The company [...]
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
23/10/2025
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to [...]
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
23/10/2025
– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR [...]

Pages